Thrivent Financial For Lutherans grew its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 7.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,460 shares of the biotechnology company’s stock after acquiring an additional 790 shares during the period. Thrivent Financial For Lutherans owned about 0.05% of Ligand Pharmaceuticals worth $1,391,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. State Board of Administration of Florida Retirement System boosted its stake in shares of Ligand Pharmaceuticals by 1.0% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 11,910 shares of the biotechnology company’s stock worth $1,261,000 after acquiring an additional 120 shares in the last quarter. US Bancorp DE grew its position in shares of Ligand Pharmaceuticals by 1.8% during the 1st quarter. US Bancorp DE now owns 3,845 shares of the biotechnology company’s stock valued at $407,000 after acquiring an additional 67 shares during the period. Swiss National Bank grew its position in shares of Ligand Pharmaceuticals by 1.9% during the 1st quarter. Swiss National Bank now owns 32,600 shares of the biotechnology company’s stock valued at $3,450,000 after acquiring an additional 600 shares during the period. Karp Capital Management Corp purchased a new position in shares of Ligand Pharmaceuticals in the 1st quarter valued at about $976,000. Finally, State of Tennessee Treasury Department increased its stake in shares of Ligand Pharmaceuticals by 17.8% in the 1st quarter. State of Tennessee Treasury Department now owns 17,811 shares of the biotechnology company’s stock valued at $1,885,000 after purchasing an additional 2,688 shares in the last quarter.

Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) opened at 137.17 on Wednesday. The stock has a market cap of $2.89 billion, a PE ratio of 334.56 and a beta of 1.01. The stock’s 50 day moving average is $132.07 and its 200-day moving average is $118.77. Ligand Pharmaceuticals Incorporated has a 1-year low of $87.50 and a 1-year high of $138.49.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.25 by $0.42. Ligand Pharmaceuticals had a return on equity of 5.05% and a net margin of 7.39%. The business had revenue of $28.00 million during the quarter, compared to analysts’ expectations of $24.40 million. During the same period last year, the firm earned $0.50 EPS. The company’s quarterly revenue was up 43.6% compared to the same quarter last year. On average, analysts predict that Ligand Pharmaceuticals Incorporated will post $2.95 EPS for the current fiscal year.

In other Ligand Pharmaceuticals news, VP Charles S. Berkman sold 18,625 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $126.96, for a total transaction of $2,364,630.00. Following the sale, the vice president now directly owns 24,423 shares in the company, valued at approximately $3,100,744.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John L. Higgins sold 5,483 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $125.00, for a total transaction of $685,375.00. Following the sale, the chief executive officer now owns 144,654 shares in the company, valued at $18,081,750. The disclosure for this sale can be found here. Insiders have sold 37,208 shares of company stock worth $4,733,796 in the last ninety days. 14.70% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/04/thrivent-financial-for-lutherans-has-1-39-million-holdings-in-ligand-pharmaceuticals-incorporated-lgnd.html.

A number of equities analysts recently weighed in on LGND shares. TheStreet raised Ligand Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, August 7th. HC Wainwright reiterated a “buy” rating and set a $150.00 price target on shares of Ligand Pharmaceuticals in a research report on Tuesday, September 5th. BidaskClub lowered Ligand Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Roth Capital raised their price objective on Ligand Pharmaceuticals from $120.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, Deutsche Bank AG raised their price objective on Ligand Pharmaceuticals from $103.00 to $104.00 and gave the company a “hold” rating in a report on Tuesday, August 8th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $133.50.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Stock Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.